» Articles » PMID: 33442273

Bacteriophages Against Pathogenic Bacteria and Possibilities for Future Application in Africa

Overview
Publisher Dove Medical Press
Date 2021 Jan 14
PMID 33442273
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Bacteriophages (phages) are viruses that infect prokaryotic cells. Phages exist in many shapes and sizes with the majority of them being less than 100 nm in size. Essentially, the majority of phages identified are double-stranded DNA virions with the remaining few being found as RNA or single-stranded DNA viruses. These biological entities are plentiful in different environments, especially in wet sources. Treatment of a bacterial disease using phage application has been documented in the pre-antibiotic era. Different studies have emerging to value the efficacy of phage use in in-vitro and in-vivo based systems against specific bacterial agents of humans, animals or plant diseases. The process represents a natural and nontoxic framework to avert infections due to pathogenic and antimicrobial-resistant bacteria. Most of the published researches on the usefulness of phages against disease-causing bacteria (including antimicrobial-resistant strains) of humans, animals or plants are emerging from the US and European countries with very few studies available from Africa. This review assesses published articles in the area of phage applications against pathogenic or antimicrobial-resistant bacteria from experimental, clinical and field settings. The knowledge and skill of isolating lytic phages against bacteria can be operational for its simpler procedures and economic benefit. Future studies in Africa and other emerging countries may consider in-house phage preparations for effective control and eradication of pathogenic and multidrug resistant bacteria of humans, animals and plants.

Citing Articles

Exploring the Microbial Ecology of Water in Sub-Saharan Africa and the Potential of Bacteriophages in Water Quality Monitoring and Treatment to Improve Its Safety.

Obongo B, Ogutu F, Hurley S, Okiko G, Mahony J Viruses. 2025; 16(12.

PMID: 39772204 PMC: 11680409. DOI: 10.3390/v16121897.


Recent developments in preventing catheter-related infections based on biofilms: A comprehensive review.

So B, Kim J, Jo J, So H Biomicrofluidics. 2024; 18(5):051506.

PMID: 39397894 PMC: 11470810. DOI: 10.1063/5.0195165.


Harnessing Bacteriophages to Combat Antibiotic-Resistant Infections in Africa: A Comprehensive Review.

Fabiyi K, Sintondji K, Agbankpe J, Assogba P, Koudokpon H, Legba B Antibiotics (Basel). 2024; 13(9).

PMID: 39334970 PMC: 11428528. DOI: 10.3390/antibiotics13090795.


The Potential of Co-Evolution and Interactions of Gut Bacteria-Phages in Bamboo-Eating Pandas: Insights from Dietary Preference-Based Metagenomic Analysis.

Zhang M, Zhou Y, Cui X, Zhu L Microorganisms. 2024; 12(4).

PMID: 38674657 PMC: 11051890. DOI: 10.3390/microorganisms12040713.


Phage Delivery Strategies for Biocontrolling Human, Animal, and Plant Bacterial Infections: State of the Art.

Vila M, Balcao L, Balcao V Pharmaceutics. 2024; 16(3).

PMID: 38543268 PMC: 10976114. DOI: 10.3390/pharmaceutics16030374.


References
1.
Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y . Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 2006; 51(2):446-52. PMC: 1797723. DOI: 10.1128/AAC.00635-06. View

2.
Svircev A, Roach D, Castle A . Framing the Future with Bacteriophages in Agriculture. Viruses. 2018; 10(5). PMC: 5977211. DOI: 10.3390/v10050218. View

3.
Malnoy M, Faize M, Venisse J, Geider K, Chevreau E . Expression of viral EPS-depolymerase reduces fire blight susceptibility in transgenic pear. Plant Cell Rep. 2004; 23(9):632-8. DOI: 10.1007/s00299-004-0855-2. View

4.
Lang J, Gent D, Schwartz H . Management of Xanthomonas Leaf Blight of Onion with Bacteriophages and a Plant Activator. Plant Dis. 2019; 91(7):871-878. DOI: 10.1094/PDIS-91-7-0871. View

5.
Sulakvelidze A, Alavidze Z, Morris Jr J . Bacteriophage therapy. Antimicrob Agents Chemother. 2001; 45(3):649-59. PMC: 90351. DOI: 10.1128/AAC.45.3.649-659.2001. View